Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease

Allison Wheeler, Shrinath Kshirsagar, Adam Giermasz, Johnny Mahlangu, Gabriela Yamaguti-Hayakawa, Savita Rangarajan, Genevieve Moyer, Christine Kempton, Almudena Tercero, Paul Sims, Sandip Panicker, Chris Foo, Eileen Sawyer, Chris Del Nagro, Gary Patou, Benjamin Kim, Nicoletta Machin

Blood (2025) 146 (Supplement 1): 308.

https://doi.org/10.1182/blood-2025-308

Published: 2025

Journal Articles

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Carolyn M Millar, Priyanka Raheja, Allison P Wheeler, Shrinath Kshirsagar, Christian Schoergenhofer, Nicoletta C Machin, Cihan Ay, Almudena Tercero, Hayley Lane, Christopher J Horvath, Sandip Panicker, Gary Patou, Benjamin Kim, Savita Rangarajan

Blood (2024) 144 (Supplement 1): 3981.

https://doi.org/10.1182/blood-2024-208020

Published: 2024

Journal Articles

Understanding Natural History of Common Inherited Platelet Function Disorder (IPFD) Patients: An Indian Study

Shrinath Kshirsagar, Nimish Kulkarni, Shruti Kharat, Kranti Patil, Savita Rangarajan, Shrimati Shetty

Blood (2023) 142 (Supplement 1): 3966.

https://doi.org/10.1182/blood-2023-182074

Published: 2023

Journal Articles

Understanding the Disease Burden of Severe Von Willebrand Disease in a Resource Poor Country: An Indian Cohort Study

Shrinath Kshirsagar, Nimish Kulkarni, Magdalne D'silva, Savita Rangarajan, Shrimati Shetty

Blood (2023) 142 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2023-179010

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Understanding Natural History of Common Inherited Platelet Function Disorder (IPFD) Patients: An Indian Study

Understanding the Disease Burden of Severe Von Willebrand Disease in a Resource Poor Country: An Indian Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: Results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease

A Phase Ia Study of VGA039, a Protein S-Targeting Monoclonal Antibody, in Individuals with Von Willebrand Disease Demonstrates Concentration-Dependent Increases in Thrombin Generation for Reducing Bleeding

Understanding Natural History of Common Inherited Platelet Function Disorder (IPFD) Patients: An Indian Study

Understanding the Disease Burden of Severe Von Willebrand Disease in a Resource Poor Country: An Indian Cohort Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only